Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+3.24%
$12.74
98% positive prob.
5-Day Prediction
+10.60%
$13.65
98% positive prob.
20-Day Prediction
+16.26%
$14.35
93% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | +3.24% | +10.60% | +16.26% | 95.8% | Pending |
| Q2 2026 | SELL | -1.71% | -6.42% | -10.56% | 99.2% | Pending |
| Q1 2026 | BUY | +2.60% | +11.28% | +18.23% | 100.0% | +3.09% |
| Q4 2025 | SELL | -2.50% | -6.69% | -9.91% | 100.0% | -4.50% |
SEC 8-K filings with transcript text
Nov 12, 2026 · 96% conf.
1D
+3.24%
$12.74
5D
+10.60%
$13.65
20D
+16.26%
$14.35
2 avah-ex99_1.htm
Exhibit 99.1
• Third Quarter Revenue was $695.5 million, an 11.8% increase over the prior year period
• Third Quarter Net income was $45.5 million compared to $14.1 million for the prior year period
• Adjusted EBITDA for Q3 2026 was $100.1 million, a 25.0% increase over the prior year period
• Increased Full Year 2026 Revenue guidance to greater than $2.695 billion, updated from greater than $2.68 billion
o Increased Full Year 2026 Adjusted EBITDA guidance to greater than $374 million, updated from greater than $365 million
Atlanta, Georgia (November 12, 2026) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and nine-month periods ended October 3, 2026.
Jeff Shaner, Chief Executive Officer, commented, “Our third quarter and year-to-date results highlight the continued momentum in our Aveanna Strategic Plan and our ability to consistently deliver sustained year-over-year growth. Revenue and Adjusted EBITDA increased 11.8% and 25.0%, respectively, compared to the prior-year period, reflecting our strong organic growth across all three business segments. Our results reinforce the strength of our operating model, the continued success of our Preferred Payor and Government Affairs strategies, and the dedication of our team to deliver exceptional care to patients and families. Given our performance through the first three quarters and confidence in our outlook, we are pleased to raise our 2026 revenue and Adjusted EBITDA guidance.”
Three-Month Periods Ended October 3, 2026 and September 27, 2025
Revenue was $695.5 million for the three-month period ended October 3, 2026, as compared to $621.9 million for the three-month period ended September 27, 2025, an increase of $73.6 million, or 11.8%. The overall increase in revenue was attributable to a $59.8 million increase in PDS segment revenue, a $9.7 million increase in HHH segment revenue, and a $4.1 million increase in MS segment revenue compared to the third quarter of 2025.
Gross margin was $226.8 million, or 32.6% of revenue, for the three-month period ended October 3, 2026, as compared to $202.8 million, or 32.6% of revenue, for the three-month period ended September 27, 2025, an increase of $23.9 million, or 11.8%.
Net income was $45.5 million or 6.5% of revenue, for the three-month period ended October 3, 2026, as compared to net income of $14.1 million, or 2.3% of revenue for the three-month period ended September 27, 2025. Net income per diluted share was $0.20 for the three-month period ended October 3, 2026, as compared to net income per diluted share of $0.06 for the three-month period ended September 27, 2025. Adjusted net income per diluted share was $0.23 for the three-month period ended October 3, 2026, as compared to adjusted net income per diluted share of $0.15 for the three-month period ended September 27, 2025. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.
Adjusted EBITDA was $100.1 million, or 14.4% of revenue, for the three-month period ended October 3, 2026, as compared to $80.1 million, or 12.9% of revenue, for the three-month period ended September 27, 2025, an increase of $20.0 million or 25.0%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.
Nine-Month Periods Ended October 3, 2026 and September 27, 2025
1
Revenue was $2,013.9 million for the nine-month period ended October 3, 2026, as compared to $1,770.7 million for the nine-month period ended September 27, 2025, an increase of $243.2 million, or 13.7%. The overall increase in revenue was attributable to a $203.4 million increase in PDS segment revenue, a $28.5 million increase in HHH segment revenue, and an $11.4 million increase in MS segment revenue compared to the first nine months of 2025.
Gross margin was $650.7 million, or 32.3% of revenue, for the nine-month period ended October 3, 2026, as compared to $597.2 million, or 33.7% of revenue, for the nine-month period ended September 27, 2025, an increase of $53.5 million, or 9.0%.
Net income was $127.4 million or 6.3% of revenue for the nine-month period ended October 3, 2026, as compared to net income of $46.3 million or 2.6% of revenue for the nine-month period ended September 27, 2025. Net income per diluted share was $0.57 for the nine-month period ended October 3, 2026, as compared to net income per diluted share of $0.22 for the nine-month period ended September 27, 2025. Adjusted net income per diluted share was $0.63 for the nine-month period ended October 3, 2026, as compared to adjusted net income per diluted share of $0.43 for the nine-month period ended September 27, 2025. See "Non-GAAP Financial Measures - Adjusted
Aug 13, 2026 · 99% conf.
1D
-1.71%
$11.10
Act: +9.12%
5D
-6.42%
$10.57
20D
-10.56%
$10.10
2 avah-ex99_1.htm
Exhibit 99.1
• Second Quarter Revenue was $670.5 million, a 13.7% increase over the prior year period
• Second Quarter Net income was $40.3 million compared to $27.0 million for the prior year period
• Adjusted EBITDA for Q2 2026 was $95.4 million, an 8.0% increase over the prior year period
• Increased Full Year 2026 Revenue guidance to greater than $2.68 billion, updated from between $2.63 and $2.65 billion
o Increased Full Year 2026 Adjusted EBITDA guidance to greater than $365 million, updated from between $338 and $342 million
Atlanta, Georgia (August 13, 2026) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and six-month periods ended July 4, 2026.
Jeff Shaner, Chief Executive Officer, commented, “Our second quarter results demonstrate the momentum across Aveanna and our ability to consistently deliver sustained year-over-year growth. Revenue and Adjusted EBITDA increased 13.7% and 8.0%, respectively, compared to the prior-year period, reflecting our strong organic growth across all three business segments. Our results reinforce the strength of our operating model, the continued success of our Preferred Payor and Government Affairs strategies, and the dedication of our team to deliver exceptional care to patients and families. Given our performance in the first half of the year and confidence in our outlook, we are pleased to raise our 2026 revenue and Adjusted EBITDA guidance.”
Three-Month Periods Ended July 4, 2026 and June 28, 2025
Revenue was $670.5 million for the three-month period ended July 4, 2026, as compared to $589.6 million for the three-month period ended June 28, 2025, an increase of $80.9 million, or 13.7%. The overall increase in revenue was attributable to a $67.9 million increase in PDS segment revenue, an $8.9 million increase in HHH segment revenue, and a $4.1 million increase in MS segment revenue compared to the second quarter of 2025.
Gross margin was $218.5 million, or 32.6% of revenue, for the three-month period ended July 4, 2026, as compared to $210.8 million, or 35.8% of revenue, for the three-month period ended June 28, 2025, an increase of $7.7 million, or 3.7%.
Net income was $40.3 million or 6.0% of revenue, for the three-month period ended July 4, 2026, as compared to net income of $27.0 million, or 4.6% of revenue for the three-month period ended June 28, 2025. Net income per diluted share was $0.18 for the three-month period ended July 4, 2026, as compared to net income per diluted share of $0.13 for the three-month period ended June 28, 2025. Adjusted net income per diluted share was $0.22 for the three-month period ended July 4, 2026, as compared to adjusted net income per diluted share of $0.18 for the three-month period ended June 28, 2025. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.
Adjusted EBITDA was $95.4 million, or 14.2% of revenue, for the three-month period ended July 4, 2026, as compared to $88.4 million, or 15.0% of revenue, for the three-month period ended June 28, 2025, an increase of $7.1 million or 8.0%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.
Six-Month Periods Ended July 4, 2026 and June 28, 2025
1
Revenue was $1,318.4 million for the six-month period ended July 4, 2026, as compared to $1,148.8 million for the six-month period ended June 28, 2025, an increase of $169.6 million, or 14.8%. The overall increase in revenue was attributable to a $143.6 million increase in PDS segment revenue, an $18.8 million increase in HHH segment revenue, and a $7.3 million increase in MS segment revenue compared to the first six months of 2025.
Gross margin was $424.0 million, or 32.2% of revenue, for the six-month period ended July 4, 2026, as compared to $394.4 million, or 34.3% of revenue, for the six-month period ended June 28, 2025, an increase of $29.6 million, or 7.5%.
Net income was $81.9 million or 6.2% of revenue for the six-month period ended July 4, 2026, as compared to net income of $32.2 million or 2.8% of revenue for the six-month period ended June 28, 2025. Net income per diluted share was $0.37 for the six-month period ended July 4, 2026, as compared to net income per diluted share of $0.16 for the six-month period ended June 28, 2025. Adjusted net income per diluted share was $0.40 for the six-month period ended July 4, 2026, as compared to adjusted net income per diluted share of $0.28 for the six-month period ended June 28, 2025. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.
Adjusted EBITDA was $179.8 million, or 13.6% of revenue, for the six-month period ended July 4, 2
May 14, 2026 · 100% conf.
1D
+2.60%
$7.63
Act: +3.83%
5D
+11.28%
$8.28
Act: +3.09%
20D
+18.23%
$8.80
Act: -4.70%
2 avah-ex99_1.htm
Exhibit 99.1
• First Quarter Revenue was $647.9 million, a 15.9% increase over the prior year period
• First Quarter Net income was $41.7 million compared to $5.2 million for the prior year period
• Adjusted EBITDA for Q1 2026 was $84.4 million, a 25.2% increase over the prior year period
• Increased Full Year 2026 Revenue guidance to between $2.56 and $2.58 billion, updated from between $2.54 and $2.56 billion
o Increased Full Year 2026 Adjusted EBITDA guidance to between $328 and $332 million, updated from between $318 and $322 million
Atlanta, Georgia (May 14, 2026) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three-month period ended April 4, 2026.
Jeff Shaner, Chief Executive Officer, commented, “Q1 reflects the strength and resiliency of our business model with an impressive start to 2026. Our first quarter results saw revenue and adjusted EBITDA increase 15.9% and 25.2%, respectively, when compared to the prior year period, and our guidance has been revised to reflect the positive momentum we see in 2026. Our Preferred Payor and Government Affairs strategies underpin the continued growth across all of our business segments. Most importantly, our clinical teams continue to deliver on our mission, bringing high quality care to our patients in the comfort of their homes. While we finalize the regulatory approval process on the Family First Homecare transaction, our focus remains on delivering strong organic growth across Aveanna’s national footprint. Finally, thank you to our Aveanna team for your hard work, dedication, and commitment to exceptional care. You are the true heart of our company."
Three-Month Period Ended April 4, 2026 and March 29, 2025
Revenue was $647.9 million for the three-month period ended April 4, 2026, as compared to $559.2 million for the three-month period ended March 29, 2025, an increase of $88.7 million, or 15.9%. The overall increase in revenue was attributable to a $75.7 million increase in PDS segment revenue, a $9.9 million increase in HHH segment revenue, and a $3.2 million increase in MS segment revenue compared to the first three months of 2025.
Gross margin was $205.4 million, or 31.7% of revenue, for the three-month period ended April 4, 2026, as compared to $183.6 million, or 32.8% of revenue, for the three-month period ended March 29, 2025, an increase of $21.9 million, or 11.9%.
Net income was $41.7 million for the three-month period ended April 4, 2026, as compared to net income of $5.2 million for the three-month period ended March 29, 2025. Net income per diluted share was $0.19 for the three-month period ended April 4, 2026, as compared to net income per diluted share of $0.03 for the three-month period ended March 29, 2025. Adjusted net income per diluted share was $0.18 for the three-month period ended April 4, 2026, as compared to adjusted net income per diluted share of $0.10 for the three-month period ended March 29, 2025. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.
Adjusted EBITDA was $84.4 million, or 13.0% of revenue, for the three-month period ended April 4, 2026, as compared to $67.4 million, or 12.0% of revenue, for the three-month period ended March 29, 2025, an increase of $17.0 million or 25.2%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.
1
Liquidity, Cash Flow, and Debt
• As of April 4, 2026, we had cash of $189.3 million and incremental borrowing capacity of $110.0 million under our securitization facility. Our revolver was undrawn, with approximately $225.5 million of borrowing capacity and approximately $24.5 million of outstanding letters of credit. The pending acquisition, which is being funded with a combination of cash on hand and borrowings under our securitization facility, is expected to reduce our liquidity upon the closing of the transaction.
• 2026 net cash provided by operating activities was $4.3 million. Free cash flow was $(3.8) million for the three-month ended April 4, 2026. See “Non-GAAP Financial Measures - Free cash flow” below.
• As of April 4, 2026 we had total indebtedness of $1,483.4 million. Our interest rate exposure under our credit facilities is currently hedged with the following instruments:
o $520.0 million notional amount of interest rate swaps that convert variable rate debt to a fixed rate, and
o $880.0 million notional amount of interest rate caps that cap our exposure to SOFR at 2.96%.
Matt Buckhalter, Chief Financial Officer, commented “We are pleased with our strong start to 2026. Our team continued to execute at a high level across all three divisions. For the first quarter, we delivered reven
This page provides Aveanna Healthcare Holdings Inc. (AVAH) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on AVAH's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.